Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Bilateral Breast Carcinoma|HER2/Neu Negative|Invasive Breast Carcinoma
Interventions: OTHER: Best Practice|DRUG: Ixabepilone
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)